Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Abbott India Dividend: In a big boost for its company shareholders, Abbott India announced a bumper final dividend of Rs 475 ...

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline: Basel Saturday, May 17, 2025, 11:00 Hrs [IST] Novartis will present data from ...

Headquartered in Basel, Novartis (NVS) is a Medical stock that has seen a price change of 17.45% so far this year. Currently paying a dividend of $2.6 per share, the company has a dividend yield of ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years.